Three-Week Monitoring After Anamorelin Initiation in Unresectable or Recurrent Pancreatic Cancer: Dietary Intake Category, Observed Body Weight, and Prognostic Nutritional Index

The authors aimed to descriptively assess the dietary intake, body weight changes, and prognostic nutritional index (PNI) in patients with unresectable or recurrent pancreatic cancer after three weeks of anamorelin treatment. They found that while body weight increased, the PNI decreased, and 40% of patients continued treatment for at least 84 days. These findings highlight the need for careful interpretation, as causal relationships cannot be established from the data.